Tag: NASDAQ: VTVT

Business

vTV Therapeutics Inc. (NASDAQ: VTVT) Jumps 7% Following Licensing Agreement With Cantex Pharmaceuticals for Azaliragon

vTV Therapeutics Inc. (NASDAQ: VTVT) jumped 6.78% after announcing the signing of a licensing agreement with Cantex Pharmaceuticals. According to the agreement, Cantex has received exclusive global rights for the development and commercialization of vTV’s antagonist of RAGE, azeliragon.  Cantex to develop and commercialize azeliragon globally  Cantex CEO and President […]